Inovio Biomedical - Jobs

No Job Openings Found For Inovio Biomedical

Jobs by

Provided by TheLadders.com

City	Title	Compensation
San Francisco	Sales Manager National specialty pharmacy is looking for a sales manager for its northern CA location. Candidates must have sales management experience from DM...	$120k
San Francisco	Sr. UNIX Platform Developer Sr. UNIX Platform DeveloperLocation: San Francisco, CA Job description:Hate spam? Love to develop high performance software? Why not combine...	$135k
San Francisco	Interactive Associate Media Director Interactive Associate Media DirectorThe AMD is a leader in the media department and emergent as a leader in the agency overall. This role has a s...	$130k
San Francisco	Senior Compensation Manager Senior Compensation Manager Location: San Francisco, California Salary: Excellent & bonus Relocation assistance provided Our client is amo...	$150k+
San Francisco	Surgical Spine Sales Representative Surgical Spine Sales with a new start-up company selling a brand new compression system on the market for a fusion procedure of the lower spine....	$200k+

BioWorld Today October 2, 2008 [BioWorld Today]
(02 Oct 2008 00:01:00 EDT)
VGX Pharmaceuticals Inc., which is set to close its reverse merger deal with publicly traded DNA vaccine firm Inovio Biomedical Corp. later this quarter, got a boost from the National Institute of Allergy and Infectious Disease in the form a $23.5 million contract for a preventative HIV DNA vaccine candidate using its electroporation technology.
BioWorld Today September 29, 2008 [BioWorld Today]
(29 Sep 2008 00:01:00 EDT)
Reverse mergers, like the one proposed by privately held ARCA Biopharma Inc. and publicly traded Nuvelo Inc. last week, are becoming a more popular route to the capital markets, especially in the stalled initial public offering market, even if they might not be investors' first exit choice.
BioWorld Today September 24, 2008 [BioWorld Today]
(24 Sep 2008 00:01:00 EDT)
, of Oslo, Norway, said that it has accomplished the second milestone in its research and licensing collaboration with F. Hoffmann-LaRoche Ltd., of Basel, Switzerland, to produce fully human recombinant antibodies against an unnamed oncology target.